Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [¹⁷⁷Lu]Lu-PSMA-617 in Healthy OrgansLu]Lu-PSMA-617 in Healthy Organs


METADATA ONLY
Loading...

Date

2024-05-23

Publication Type

Journal Article

ETH Bibliography

yes

Citations

Altmetric
METADATA ONLY

Data

Rights / License

Abstract

Prostate-specific membrane antigen (PSMA)-targeted radio ligand therapeutics (RLTs), such as [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto), have been shown to accumulate in salivary glands and kidneys, potentially leading to undesired side effects. As unwanted accumulation in normal organs may derive from the cross-reactivity of PSMA ligands to glutamate carboxypeptidase III (GCPIII), it may be convenient to block this interaction with GCPIII-selective ligands. Parallel screening of a DNA-encoded chemical library (DEL) against GCPIII and PSMA allowed the identification of GCPIII binders. Structure–activity relationship (SAR) studies resulted in the identification of nanomolar GCPIII ligands with up to 1000-fold selectivity over PSMA. We studied the ability of GCPIII ligands to counteract the binding of [¹⁷⁷Lu]Lu-PSMA-617 to human salivary glands by autoradiography and could demonstrate a partial radioprotection.

Permanent link

Publication status

published

Editor

Book title

Volume

67 (10)

Pages / Article No.

8247 - 8260

Publisher

American Chemical Society

Event

Edition / version

Methods

Software

Geographic location

Date collected

Date created

Subject

Cancer; Fluorescence; Ligands; Monomers; Peptides and proteins

Organisational unit

Notes

Funding

Related publications and datasets